KR950700746A - 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy) - Google Patents

양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)

Info

Publication number
KR950700746A
KR950700746A KR1019940703522A KR19940703522A KR950700746A KR 950700746 A KR950700746 A KR 950700746A KR 1019940703522 A KR1019940703522 A KR 1019940703522A KR 19940703522 A KR19940703522 A KR 19940703522A KR 950700746 A KR950700746 A KR 950700746A
Authority
KR
South Korea
Prior art keywords
compositions
methods
benign prostatic
prostatic hypertrophy
treating benign
Prior art date
Application number
KR1019940703522A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700746A publication Critical patent/KR950700746A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
KR1019940703522A 1992-04-02 1994-10-04 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy) KR950700746A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86211792A 1992-04-02 1992-04-02
US99779292A 1992-12-29 1992-12-29
PCT/US1993/003145 WO1993019758A1 (en) 1992-04-02 1993-04-02 Compositions and methods for treating benign prostatic hypertrophy

Publications (1)

Publication Number Publication Date
KR950700746A true KR950700746A (ko) 1995-02-20

Family

ID=27127672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703522A KR950700746A (ko) 1992-04-02 1994-10-04 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)

Country Status (8)

Country Link
EP (1) EP0633781A4 (ko)
JP (1) JPH07505398A (ko)
KR (1) KR950700746A (ko)
AU (1) AU668157B2 (ko)
CA (1) CA2133440A1 (ko)
MX (1) MX9301939A (ko)
NZ (1) NZ251658A (ko)
WO (1) WO1993019758A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
AU7719894A (en) * 1993-09-03 1995-03-22 Smithkline Beecham Corporation Stabilized tablet formulation
WO1995028397A1 (en) * 1994-04-14 1995-10-26 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4963547A (en) * 1988-06-01 1990-10-16 Smithkline Beecham Corporation Alpha-andrenergic receptor antagonists and use thereas
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury

Also Published As

Publication number Publication date
EP0633781A4 (en) 1995-04-19
WO1993019758A1 (en) 1993-10-14
AU3945193A (en) 1993-11-08
NZ251658A (en) 1996-08-27
EP0633781A1 (en) 1995-01-18
AU668157B2 (en) 1996-04-26
CA2133440A1 (en) 1993-10-14
JPH07505398A (ja) 1995-06-15
MX9301939A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
EP0667769A4 (en) USE OF SPECIFIC ALPHA-1C COMPOUNDS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA.
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
HUP0001454A3 (en) Compositions and methods for treating plants with exogenous chemicals
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
EP0611302A4 (en) METHODS AND COMPOSITIONS FOR TREATING ALLERGIC REACTIONS.
IS2012B (is) Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
DE69426772T2 (de) Kohlensäureanhydrid erzeugende Zusammensetzungen
EP0758196A4 (en) COMPOSITIONS AND METHODS FOR TREATING TUMORS
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
BR9407124A (pt) Composições contendo surfactante
NO951718D0 (no) Fremgangsmåter og sammensetninger av (+)doksazosin for behandling av godartet hyperplasi og aterosklerose
FI965008A0 (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
KR950700746A (ko) 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)
EP0462668A3 (en) New 17beta-aminobenzoyl-4-aza-5alpha-androst-1-en-3-ones as benign prostatic hypertrophy agents
PL342339A1 (en) Novel substituted pyridino-aryl piperazines useful in treating benign prostatic hypertrophy
NO901272D0 (no) Sammensetning og fremgangsmaate for fjerning av sulfider.
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
PL324172A1 (en) Malatonin agonists for treating mild forms of prostatic hypertrophy
KR950701012A (ko) 금속을 처리하기 위한 조성물 및 방법(composition and process for treating metal)
NO952766D0 (no) Opplösningsmiddelsammensetninger og metoder
ZA922010B (en) Improved method of treatment for benign prostatic hyperplasia
AUPO410796A0 (en) Method of treating benign prostatic hyperplasia

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid